{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T22:43:48Z","timestamp":1792622628202,"version":"4.5.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,3,23]],"date-time":"2020-03-23T00:00:00Z","timestamp":1584921600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,3,23]],"date-time":"2020-03-23T00:00:00Z","timestamp":1584921600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1007\/s40259-020-00416-z","type":"journal-article","created":{"date-parts":[[2020,3,23]],"date-time":"2020-03-23T14:02:58Z","timestamp":1584972178000},"page":"235-244","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Certolizumab Pegol: A Review in Moderate to Severe Plaque Psoriasis"],"prefix":"10.1007","volume":"34","author":[{"given":"Arnold","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lesley J.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,23]]},"reference":[{"issue":"3","key":"416_CR1","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.jaci.2017.07.004","volume":"140","author":"JE Hawkes","year":"2017","unstructured":"Hawkes JE, Chan TC, Krueger JG. Psoriasis pathogenesis and the development of novel targeted immune therapies. J Allergy Clin Immunol. 2017;140(3):645\u201353.","journal-title":"J Allergy Clin Immunol."},{"issue":"9997","key":"416_CR2","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/S0140-6736(14)61909-7","volume":"386","author":"W-H Boehncke","year":"2015","unstructured":"Boehncke W-H, Sch\u00f6n MP. Psoriasis. Lancet. 2015;386(9997):983\u201394.","journal-title":"Lancet"},{"key":"416_CR3","unstructured":"UCB Inc. Certolizumab pegol (Cimzia): US prescribing information. 2019. \n                  http:\/\/www.cimzia.com\n                  \n                . Accessed 14 Feb 2020."},{"key":"416_CR4","unstructured":"European Medicines Agency. Certolizumab pegol (Cimzia): EU summary of product characteristics. 2019. \n                  http:\/\/www.ema.europa.eu\n                  \n                . Accessed 21 Aug 2019."},{"issue":"9","key":"416_CR5","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1007\/s40265-014-0239-z","volume":"74","author":"S Dhillon","year":"2014","unstructured":"Dhillon S. Certolizumab pegol: a review of its use in patients with axial spondyloarthritis or psoriatic arthritis. Drugs. 2014;74(9):999\u20131016.","journal-title":"Drugs"},{"issue":"6","key":"416_CR6","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s40259-016-0197-y","volume":"30","author":"ED Deeks","year":"2016","unstructured":"Deeks ED. Certolizumab pegol: a review in inflammatory autoimmune diseases. BioDrugs. 2016;30(6):607\u201317.","journal-title":"BioDrugs"},{"issue":"1","key":"416_CR7","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s40265-013-0009-3","volume":"73","author":"ED Deeks","year":"2013","unstructured":"Deeks ED. Certolizumab pegol: a review of its use in the management of rheumatoid arthritis. Drugs. 2013;73(1):75\u201397.","journal-title":"Drugs"},{"issue":"S1","key":"416_CR8","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s40259-013-0064-z","volume":"28","author":"G Pasut","year":"2014","unstructured":"Pasut G. Pegylation of biological molecules and potential benefits: pharmacological properties of certolizumab pegol. BioDrugs. 2014;28(S1):15\u201323.","journal-title":"BioDrugs"},{"issue":"2","key":"416_CR9","doi-asserted-by":"publisher","first-page":"266.e5","DOI":"10.1016\/j.jaad.2018.04.013","volume":"79","author":"M Lebwohl","year":"2018","unstructured":"Lebwohl M, Blauvelt A, Paul C, et al. Certolizumab pegol for the treatment of chronic plaque psoriasis: results through 48\u00a0weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT). J Am Acad Dermatol. 2018;79(2):266.e5\u2013276.e5.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"416_CR10","doi-asserted-by":"publisher","first-page":"302.e6","DOI":"10.1016\/j.jaad.2018.04.012","volume":"79","author":"AB Gottlieb","year":"2018","unstructured":"Gottlieb AB, Blauvelt A, Thaci D, et al. Certolizumab pegol for the treatment of chronic plaque psoriasis: results through 48\u00a0weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2). J Am Acad Dermatol. 2018;79(2):302.e6\u2013314.e6.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"416_CR11","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1111\/j.1365-2133.2012.10941.x","volume":"167","author":"K Reich","year":"2012","unstructured":"Reich K, Ortonne JP, Gottlieb AB, et al. Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab\u2019 certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension. Br J Dermatol. 2012;167(1):180\u201390.","journal-title":"Br J Dermatol"},{"key":"416_CR12","unstructured":"Umezawa Y, Sakurai S, Hoshii N, et al. Efficacy of certolizumab pegol in Japanese patients with plaque psoriasis: 16\u00a0week data from a phase 2\/3, multicentre, randomised, double-blind, placebo-controlled study [abstract]. Japanese Society for Psoriasis Research Meeting. 2019."},{"issue":"3","key":"416_CR13","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1111\/jdv.15258","volume":"33","author":"A Blauvelt","year":"2019","unstructured":"Blauvelt A, Reich K, Lebwohl M, et al. Certolizumab pegol for the treatment of patients with moderate-to-severe chronic plaque psoriasis: pooled analysis of week 16 data from three randomized controlled trials. J Eur Acad Dermatol Venereol. 2019;33(3):546\u201352.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"416_CR14","doi-asserted-by":"crossref","unstructured":"Augustin M, Weglowska J, Lebwohl M, et al. Clinical response in plaque psoriasis patients switching from etanercept to certolizumab pegol in a phase 3, randomized, controlled study [abstract plus poster]. SKIN. 2018;2(Suppl).","DOI":"10.25251\/skin.2.supp.87"},{"key":"416_CR15","doi-asserted-by":"crossref","unstructured":"Piguet V, Blauvelt A, Burge D, et al. Certolizumab pegol for the treatment of chronic plaque psoriasis: DLQI And WPAI patient-reported outcomes from an ongoing phase 3, multicenter, randomized, active- and placebo-controlled study (CIMPACT) [abstract no. 146 plus poster]. SKIN. 2017;1(Suppl).","DOI":"10.25251\/skin.1.supp.2"},{"issue":"1","key":"416_CR16","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1159\/000365390","volume":"230","author":"MKA Basra","year":"2015","unstructured":"Basra MKA, Salek MS, Camilleri L, et al. Determining the minimal clinically important difference and responsiveness of the Dermatology Life Quality Index (DLQI): further data. Dermatology. 2015;230(1):27\u201333.","journal-title":"Dermatology"},{"key":"416_CR17","doi-asserted-by":"crossref","unstructured":"Thaci D, Gottlieb A, Reich K, et al. Certolizumab pegol for the treatment of chronic plaque psoriasis: DLQI and WPAI patient-reported outcomes from two ongoing phase 3, multicenter, randomized, placebo-controlled studies (CIMPASI-1 and CIMPASI-2) [abstract no. 212 plus poster]. SKIN. 2017;1(Suppl).","DOI":"10.25251\/skin.1.supp.3"},{"key":"416_CR18","unstructured":"European Medicines Agency. Cimzia: assessment report (EMEA\/H\/C\/001037\/II\/0065). 2018. \n                  http:\/\/www.ema.europa.eu\n                  \n                . Accessed 10 May 2019."},{"key":"416_CR19","doi-asserted-by":"crossref","unstructured":"Augustin M, Weg\u0142owska J, Lebwohl M, et al. Durability of response in patients with chronic plaque psoriasis treated with certolizumab pegol over 48\u00a0weeks: pooled results from ongoing phase 3, multicentre, randomised, placebo-controlled studies (CIMPASI-1, CIMPASI-2 and CIMPACT) [abstract plus poster]. SKIN. 2018;2(Suppl).","DOI":"10.25251\/skin.2.supp.88"},{"key":"416_CR20","unstructured":"European Medicines Agency. Guideline on clinical investigation of medicinal products indicated for the treatment of psoriasis. 2004. \n                  http:\/\/www.ema.europa.eu\n                  \n                . Accessed 28 Jan 2020."},{"key":"416_CR21","doi-asserted-by":"crossref","unstructured":"Augustin M, Weg\u0142owska J, Lebwohl M, et al. Maintenance of response with certolizumab pegol for the treatment of chronic plaque psoriasis: results of a 32-week re-randomized maintenance period from an ongoing phase 3, multicenter randomized, active- and placebo-controlled study (CIMPACT) [abstract plus poster]. SKIN. 2017;1(Suppl).","DOI":"10.25251\/skin.1.supp.23"},{"key":"416_CR22","unstructured":"Augustin M, Lebwohl M, Piguet V, et al. Efficacy of certolizumab pegol dose escalation in patients who inadequately respond to initial treatment: results from the CIMPACT trial [abstract plus poster]. AAD Meeting. 2019."},{"key":"416_CR23","doi-asserted-by":"crossref","unstructured":"Gottlieb AB, Thaci D, Leonardi C, et al. Nail outcome improvements with certolizumab pegol in moderate to severe plaque psoriasis: results from phase 3 trials [abstract] [abstract no. P116]. J Eur Acad Dermatol Venereol. 2019.","DOI":"10.25251\/skin.3.supp.38"},{"key":"416_CR24","doi-asserted-by":"crossref","unstructured":"Gordon K, Warren RB, Gottlieb AB, et al. Certolizumab pegol for treatment of plaque psoriasis: pooled three-year efficacy outcomes from the intent-to-treat population of two phase 3 trials (CIMPASI-1 and CIMPASI-2) [oral presentation]. EADV Congress. 2019.","DOI":"10.25251\/skin.3.supp.37"},{"issue":"1","key":"416_CR25","doi-asserted-by":"publisher","first-page":"e000119","DOI":"10.1136\/rmdopen-2015-000119","volume":"1","author":"P Mease","year":"2015","unstructured":"Mease P, Deodhar A, Fleischmann R, et al. Effect of certolizumab pegol over 96\u00a0weeks in patients with psoriatic arthritis with and without prior antitumour necrosis factor exposure. RMD Open. 2015;1(1):e000119.","journal-title":"RMD Open"},{"issue":"1","key":"416_CR26","doi-asserted-by":"publisher","first-page":"e000582","DOI":"10.1136\/rmdopen-2017-000582","volume":"4","author":"D van der Heijde","year":"2018","unstructured":"van der Heijde D, Deodhar A, FitzGerald O, et al. 4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis. RMD Open. 2018;4(1):e000582.","journal-title":"RMD Open"},{"issue":"1","key":"416_CR27","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1136\/annrheumdis-2013-203660","volume":"74","author":"VP Bykerk","year":"2015","unstructured":"Bykerk VP, Cush J, Winthrop K, et al. Update on the safety profile of certolizumab pegol in rheumatoid arthritis: an integrated analysis from clinical trials. Ann Rheum Dis. 2015;74(1):96\u2013103.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"416_CR28","doi-asserted-by":"publisher","first-page":"e000942","DOI":"10.1136\/rmdopen-2019-000942","volume":"5","author":"JR Curtis","year":"2019","unstructured":"Curtis JR, Mariette X, Gaujoux-Viala C, et al. Long-term safety of certolizumab pegol in rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis and Crohn\u2019s disease: a pooled analysis of 11,317 patients across clinical trials. RMD Open. 2019;5(1):e000942.","journal-title":"RMD Open"},{"key":"416_CR29","doi-asserted-by":"crossref","unstructured":"Blauvelt A, Paul C, Kerkhof Pvd, et al. Long-term safety of certolizumab pegol in plaque psoriasis: pooled analysis over 3\u00a0years from three phase 3, randomized, placebo-controlled studies [abstract plus poster]. SKIN. 2020;4(Suppl 3).","DOI":"10.1111\/bjd.19314"},{"key":"416_CR30","unstructured":"National Institute for Health and Care Excellence. Psoriasis: assessment and management. 2017. \n                  http:\/\/www.nice.org.uk\/guidance\/cg153\n                  \n                . Accessed 10 Jul 2019."},{"issue":"3","key":"416_CR31","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1111\/jdv.15340","volume":"33","author":"F Amatore","year":"2019","unstructured":"Amatore F, Villani AP, Tauber M, et al. French guidelines on the use of systemic treatments for moderate-to-severe psoriasis in adults. J Eur Acad Dermatol Venereol. 2019;33(3):464\u201383.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"416_CR32","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1111\/bjd.15665","volume":"177","author":"CH Smith","year":"2017","unstructured":"Smith CH, Jabbar-Lopez ZK, Yiu ZZ, et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017. Br J Dermatol. 2017;177(3):628\u201336.","journal-title":"Br J Dermatol"},{"issue":"12","key":"416_CR33","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1111\/jdv.13354","volume":"29","author":"A Nast","year":"2015","unstructured":"Nast A, Gisondi P, Ormerod A, et al. European S3-Guidelines on the systemic treatment of psoriasis vulgaris\u2014update 2015 short version. EDF in cooperation with EADV and IPC. J Eur Acad Dermatol Venereol. 2015;29(12):2277\u201394.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"11","key":"416_CR34","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1038\/jid.2015.206","volume":"2019","author":"A Nast","year":"2015","unstructured":"Nast A, Jacobs A, Rosumeck S, et al. Efficacy and safety of systemic long-term treatments for moderate-to-severe psoriasis: a systematic review and meta-analysis. J Invest Dermatol. 2015;2019(11):2641\u20138.","journal-title":"J Invest Dermatol"},{"key":"416_CR35","unstructured":"National Institute for Health and Care Excellence. Certolizumab pegol for treating moderate to severe plaque psoriasis. 2019. \n                  http:\/\/www.nice.org.uk\/guidance\/ta574\n                  \n                . Accessed 10 Jul 2019."},{"key":"416_CR36","first-page":"CD011535","volume":"12","author":"E Sbidian","year":"2017","unstructured":"Sbidian E, Chaimani A, Garcia-Doval I, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev. 2017;12:CD011535.","journal-title":"Cochrane Database Syst Rev"},{"issue":"S1","key":"416_CR37","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/bjd.17752","volume":"181","author":"S Mahil","year":"2019","unstructured":"Mahil S, Ezejimofor M, Exton L, et al. Comparing the efficacy and tolerability of biological therapies in psoriasis: an updated network meta-analysis [abstract no. P096]. Br J Dermatol. 2019;181(S1):25\u201375.","journal-title":"Br J Dermatol"},{"key":"416_CR38","unstructured":"European Medicines Agency. Adalimumab (Humira): EU summary of product characteristics. 2020. \n                  http:\/\/www.ema.europa.eu\n                  \n                . Accessed 14 Feb 2020."},{"key":"416_CR39","unstructured":"European Medicines Agency. Ustekinumab (Stelara): EU summary of product characteristics. 2020. \n                  http:\/\/www.ema.europa.eu\n                  \n                . Accessed 14 Feb 2020."},{"key":"416_CR40","unstructured":"European Medicines Agency. Infliximab (Remicade): EU summary of product characteristics. 2019. \n                  http:\/\/www.ema.europa.eu\n                  \n                . Accessed 14 Nov 2019."},{"key":"416_CR41","unstructured":"European Medicines Agency. Etanercept (Benepali): EU summary of product characteristics. 2020. \n                  http:\/\/www.ema.europa.eu\n                  \n                . Accessed 14 Feb 2020."},{"key":"416_CR42","unstructured":"European Medicines Agency. Brodalumab (Kyntheum): EU summary of product characteristics. 2019. \n                  http:\/\/www.ema.europa.eu\n                  \n                . Accessed 14 Nov 2019."},{"key":"416_CR43","unstructured":"European Medicines Agency. Ixekizumab (Taltz): EU summary of product characteristics. 2019. \n                  http:\/\/www.ema.europa.eu\n                  \n                . Accessed 14 Nov 2019."},{"key":"416_CR44","unstructured":"European Medicines Agency. Secukinumab (Cosentyx): EU summary of product characteristics. 2019. \n                  http:\/\/www.ema.europa.eu\n                  \n                . Accessed 14 Nov 2019."},{"key":"416_CR45","doi-asserted-by":"crossref","unstructured":"European Medicines Agency. Guselkumab (Tremfya): EU summary of product characteristics. 2020. \n                  http:\/\/www.ema.europa.eu\n                  \n                . Accessed 14 Feb 2020.","DOI":"10.36290\/der.2020.003"},{"key":"416_CR46","unstructured":"European Medicines Agency. Tildrakizumab (Ilumetri): EU summary of product characteristics. 2019. \n                  http:\/\/www.ema.europa.eu\n                  \n                . Accessed 21 Aug 2019."},{"key":"416_CR47","unstructured":"European Medicines Agency. Risankizumab (Skyrizi): EU summary of product characteristics. 2019. \n                  http:\/\/www.ema.europa.eu\n                  \n                . Accessed 14 Nov 2019."},{"issue":"4","key":"416_CR48","doi-asserted-by":"publisher","first-page":"e380","DOI":"10.1016\/S2214-109X(18)30029-9","volume":"6","author":"J Bearak","year":"2018","unstructured":"Bearak J, Popinchalk A, Alkema L, et al. Global, regional, and subregional trends in unintended pregnancy and its outcomes from 1990 to 2014: estimates from a Bayesian hierarchical model. Lancet Glob Health. 2018;6(4):e380\u20139.","journal-title":"Lancet Glob Health"},{"issue":"7605","key":"416_CR49","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1136\/bmj.39202.518484.80","volume":"334","author":"S Weatherhead","year":"2007","unstructured":"Weatherhead S, Robson SC, Reynolds NJ. Management of psoriasis in pregnancy. BMJ. 2007;334(7605):1218\u201320.","journal-title":"BMJ"}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-020-00416-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40259-020-00416-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-020-00416-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,27]],"date-time":"2020-06-27T19:17:25Z","timestamp":1593285445000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40259-020-00416-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,23]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["416"],"URL":"https:\/\/doi.org\/10.1007\/s40259-020-00416-z","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,23]]},"assertion":[{"value":"23 March 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Arnold Lee and Lesley Scott are salaried employees of Adis International Ltd\/Springer Nature, are responsible for the article content and declare no relevant conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}